AAPM TG158: Measurement and calculation of doses outside the treated volume from external‐beam radiation therapy

Citations Over TimeTop 1% of 2017 papers

Abstract

The introduction of advanced techniques and technology in radiotherapy has greatly improved our ability to deliver highly conformal tumor doses while minimizing the dose to adjacent organs at risk. Despite these tremendous improvements, there remains a general concern about doses to normal tissues that are not the target of the radiation treatment; any "nontarget" radiation should be minimized as it offers no therapeutic benefit. As patients live longer after treatment, there is increased opportunity for late effects including second cancers and cardiac toxicity to manifest. Complicating the management of these issues, there are unique challenges with measuring, calculating, reducing, and reporting nontarget doses that many medical physicists may have limited experience with. Treatment planning systems become dramatically inaccurate outside the treatment field, necessitating a measurement or some other means of assessing the dose. However, measurements are challenging because outside the treatment field, the radiation energy spectrum, dose rate, and general shape of the dose distribution (particularly the percent depth dose) are very different and often require special consideration. Neutron dosimetry is also particularly challenging, and common errors in methodology can easily manifest as errors of several orders of magnitude. Task Group 158 was, therefore, formed to provide guidance for physicists in terms of assessing and managing nontarget doses. In particular, the report: (a) highlights major concerns with nontarget radiation; (b) provides a rough estimate of doses associated with different treatment approaches in clinical practice; (c) discusses the uses of dosimeters for measuring photon, electron, and neutron doses; (d) discusses the use of calculation techniques for dosimetric evaluations; (e) highlights techniques that may be considered for reducing nontarget doses; (f) discusses dose reporting; and (g) makes recommendations for both clinical and research practice.

Related Papers

• → How quality influences the clinical outcome of external beam radiotherapy for localized prostate cancer(2008)3 cited
• → Complications of Treatment with Local Field External Beam Radiotherapy for Localized Prostate Cancer(2000)1 cited
• → 282 Intra-prostatic gold markers for position-verification of the prostate gland in dose escalated external beam radiotherapy (EBRT)(2005)
• → Comparison Of External Beam Radiotherapy Followed By Intra-Luminal Brachytherapy With External Beam Radiotherapy Alone In Locally Advanced Carcinoma Of Esophagus(2017)
• → 18 Effect of bladder filling on isocentre displacement in prostate External Beam Radiotherapy (EBRT)(2003)